Get notified when WST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Related Party (new) — The agreements are with Daikyo, in which West holds a 49% ownership stake, making this a related-party transaction that warrants scrutiny of terms and governance.
West Pharmaceutical renews 10-year technology and distribution pact with 49%-owned Daikyo
Filed July 14, 2026 · Period ending July 14, 2026 · ~1 min read
Key Changes
-
high
West renewed technology-sharing, crosslicensing, and distribution agreements with Daikyo Seiko, in which West holds a 49% ownership stake, for another 10 years through 2036.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
West receives exclusive license to Daikyo's pharmaceutical packaging technology outside Japan and exclusive global distribution rights for Daikyo products; Daikyo gets non-exclusive license to West's technology and non-exclusive distribution rights in Japan.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Agreements are largely royalty-free except for certain patents and technical information; either party can terminate upon change of control or mutual consent.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NKE 10-K) is open in full — no account needed.
Partner
Trade WST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 16, 2026 · How we verify